Tremelimumab (day 1 only) and durvalumab in combination with transarterial chemoemobilization (TACE) in patients with hepatocellular carcinoma (HCC).-MedSci.cn

Tremelimumab (day 1 only) and durvalumab in combination with transarterial chemoemobilization (TACE) in patients with hepatocellular carcinoma (HCC).

Buchalter, J; Evans, N; Browne, I; Mac Eochagain, C; Flynn, C; Carroll, HK; Galligan, M; Bourke, M; Lester-Grant, A; Hoey, K; Ryan, R; Cantwell, CP; McCann, J; McDermott, R; MacNicholas, R; Duffy, AG

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (16): E16175

科室
- - 订阅+
  - 更多科室
工具
服务